Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04398628
Other study ID # ATHN Transcends
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date September 30, 2020
Est. completion date December 2035

Study information

Verified date June 2024
Source American Thrombosis and Hemostasis Network
Contact Carol Fedor, ND, RN, CCRC
Phone 800-360-2846
Email cfedor@athn.org
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

In parallel with the growth of American Thrombosis and Hemostasis Network's (ATHN) clinical studies, the number of new therapies for all congenital and acquired hematologic conditions, not just those for bleeding and clotting disorders, is increasing significantly. Some of the recently FDA-approved therapies for congenital and acquired hematologic conditions have yet to demonstrate long-term safety and effectiveness beyond the pivotal trials that led to their approval. In addition, results from well-controlled, pivotal studies often cannot be replicated once a therapy has been approved for general use.(1,2,3,4) In 2019 alone, the United States Food and Drug Administration (FDA) has issued approvals for twenty-four new therapies for congenital and acquired hematologic conditions.(5) In addition, almost 10,000 new studies for hematologic diseases are currently registered on www.clinicaltrials.gov.(6) With this increase in potential new therapies on the horizon, it is imperative that clinicians and clinical researchers in the field of non-neoplastic hematology have a uniform, secure, unbiased, and enduring method to collect long-term safety and efficacy data. ATHN Transcends is a cohort study to determine the safety, effectiveness, and practice of therapies used in the treatment of participants with congenital or acquired non-neoplastic blood disorders and connective tissue disorders with bleeding tendency. The study consists of 7 cohorts with additional study "arms" and "modules" branching off from the cohorts. The overarching objective of this longitudinal, observational study is to characterize the safety, effectiveness and practice of treatments for all people with congenital and acquired hematologic disorders in the US. As emphasized in a recently published review, accurate, uniform and quality national data collection is critical in clinical research, particularly for longitudinal cohort studies covering a lifetime of biologic risk.(7)


Description:

This is a longitudinal, natural history observational cohort study being conducted at approximately 150 ATHN-affiliated sites. Participants will be followed for a minimum of 15 years. Harmonized data elements will be collected at the time of enrollment, quarterly, annually, and ad hoc. Base data will be collected for all participants. Specific data will be collected for participants enrolled in cohort-specific Arms and Modules. Each participant will be assigned to a single cohort: Hemophilia, Von Willebrand Disease, Congenital Platelet Disorders, Rare Disorders, Bleeding Not Otherwise Specified (NOS), Thrombosis/Thrombophilia, or Non-Neoplastic Hematologic Conditions. Study Arms and study Modules may be developed to provision disease and/or disease specific insights related to stakeholders, including but not limited to pharmaceutical companies, ATHN, and Hemophilia Treatment Centers (HTCs). Arms may branch off into product-specific data collection via Modules to be collected during the study, in conjunction with planned study assessments. ATHN Transcends Principal Investigators Tammuella Chrisentery-Singleton, MD Ochsner Clinic Foundation American Thrombosis and Hemostasis Network Michael Recht, MD, PhD, MBA Yale University School of Medicine National Bleeding Disorders Foundation PUPs Arm: Co-Principal Investigators: Shannon Carpenter, MD, MS University of Missouri Kansas City School of Medicine Children's Mercy Hospital Julie Jaffray, MD University of California San Diego Rady Children's Hospital San Diego ALTUVIIO Module: Co-Principal Investigators Shannon Carpenter, MD, MS University of Missouri Kansas City School of Medicine Children's Mercy Hospital Co-Principal Investigator Julie Jaffray, MD University of California San Diego Rady Children's Hospital San Diego INHIBIT Module: Co-Principal Investigators: Nicoletta Machin DO, MS Assistant Professor, Division of Hematology/Oncology Hemophilia Center of Western Pennsylvania University of Pittsburgh Medical Center Hemophilia Natural History Arm: Co-Principal Investigators: Tyler Buckner, MD, MSc Hemophilia and Thrombosis Center University of Colorado Anschutz Medical Campus Michael Recht, MD, PhD, MBA Yale University School of Medicine National Bleeding Disorders Foundation Rebinyn Module Co-Principal Investigators: Lauren Amos, MD Children's Mercy Hospital, Kansas City Guy Young, MD University of Southern California Children's Hospital Los Angeles Hemophilia Gene Therapy Outcomes Arm: Co-Principal Investigators: Janice M. Staber, MD Iowa Hemophilia and Thrombosis Center University of Iowa Stead Family Children's Hospital Ulrike M. Reiss, MD Hemophilia Treatment Center St. Jude's Children's Research Hospital Severe VWD Natural History Arm: Co-Principal Investigators: Robert F. Sidonio, Jr., MD, MSc Aflac Cancer and Blood Disorders Center, Hemophilia of Georgia Center for Bleeding and Clotting Disorders Angela C. Weyand, MD C.S. Mott Children's Hospital, University of Michigan Medical School, Ann Arbor Congenital Platelet Disorders Natural History Arm: Principal Investigator Sanjay Ahuja, MD Rainbow Babies & Children's Hospital, Case Western Reserve University Glanzmann Thrombasthenia Module: Co-Principal Investigators: Divya Citla-Sridhar, MD University of Arkansas for Medical Sciences Arkansas Children's Hospital Meera Chitlur, MD Children's Hospital of Michigan Hemophilia Cohort This cohort includes three Arms and five Modules: Previously Untreated Patients (PUPs) Arm This is a pediatric focused Arm of PUPs with hemophilia A or B. ALTUVIIIO® Module The purpose is to investigate the safety and effectiveness of ALTUVIIIO® in PUPs with hemophilia A. INHIBIT Module This is an observational study assessing inhibitor formation in children with severe hemophilia A. Hemophilia Natural History Arm This Arm is investigating the safety, effectiveness, and practice of treatment for people with hemophilia. Hemlibra® Module All participants treated with Hemlibra® are eligible to participate. Rebinyn® Module The Rebinyn® Module is a prospective study in hemophilia B participants without inhibitors. Hemophilia Gene Therapy Outcomes Arm This Arm is investigating the safety and effectiveness of gene therapy in people with hemophilia. HEMGENIX® Module This is an observational study to characterize the effectiveness and safety of HEMGENIX® in participants with hemophilia B. Congenital Platelet Disorders (CPD) Natural History Arm: The CPD Arm is investigating the safety and efficacy of hemostatic therapies in the prevention or treatment of bleeding events in adult and pediatric participants with inherited congenital platelet disorders. Glanzmann Thrombasthenia (GT) Module: This Module is a study of bleeding symptoms, treatments, and treatment outcomes in patients with Glanzmann thrombasthenia. Von Willebrand Disease Cohort No arms or modules open at this time. Rare Disorders Cohort No arms or modules open at this time. Bleeding NOS No arms or modules open at this time. Thrombosis/Thrombophilia No arms or modules open at this time. Non-Neoplastic Hematologic Conditions No arms or modules open at this time.


Recruitment information / eligibility

Status Recruiting
Enrollment 3000
Est. completion date December 2035
Est. primary completion date June 2035
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Participants who meet the following inclusion criteria and none of the exclusion criteria are eligible for enrollment in the base study: Inclusion Criteria: 1. Any age 2. Having a congenital or acquired non-neoplastic hematologic disorder; or 3. Having a bleeding phenotype as indicated by an age adjusted abnormal ISTH Bleeding Assessment Tool score with an unknown diagnosis; or 4. Connective tissue disorder with bleeding tendency as indicated by an age adjusted abnormal ISTH Bleeding Assessment Tool score. Exclusion Criteria: 1. Does not qualify for inclusion in a cohort 2. Unable to give informed consent or assent 3. Unwilling to perform study procedures Cohort Participant Selection Each participant is to be enrolled in the cohort for which they qualify as defined below. Hemophilia Cohort Inclusion Criteria: Participants who meet any of the following inclusion criteria are eligible for enrollment into this cohort: 1. Factor VIII or factor IX activity < 50%, without another explanation for low clotting factor other than congenital hemophilia or being a known carrier for congenital hemophilia; OR 2. Being a known carrier for congenital hemophilia with a factor VIII or factor IX activity greater than or equal to 50% with or without a bleeding phenotype as indicated by an age-adjusted abnormal ISTH Bleeding Assessment Tool score; OR 3. Known congenital hemophilia that have a factor level >50% after receiving vector; OR 4. Acquired hemophilia Exclusion Criteria: None Von Willebrand Disease Cohort Inclusion Criteria: Participants who meet the following inclusion criteria are eligible for enrollment into this cohort: 1. Meeting the definition of VWD or low VWF per most recent international guidelines Exclusion Criteria: None Congenital Platelet Disorders Cohort Inclusion Criteria: Participants who meet the following inclusion criteria are eligible for enrollment into this cohort: 1. Abnormalities of platelet function 1. Glanzmann thrombasthenia (GPIIb or GPIIIa) 2. Bernard-Soulier syndrome (GPIbalpha, GPIbbeta, or GPIX) 2. Abnormalities of platelet granules 3. Abnormalities of platelet signal transduction 4. Abnormalities of platelet secretion 5. Collagen Receptor Defect 6. ADP Receptor Defect 7. Thromboxane Receptor Defect 8. Giant Platelet Disorder 9. Abnormalities in platelet aggregation testing due to another or unknown cause (not drug related) Exclusion Criteria: Platelet disorders secondary to medications or other substances Rare Disorders Cohort Inclusion Criteria: Participants who meet the following inclusion criteria are eligible for enrollment into this cohort: 1. Have an established Rare Coagulation Disorder (RCD) diagnosis of one of the following: 1. PAI-1 deficiency 2. Factor I, II, V, VII, X, XI, XIII deficiencies 3. Combined FV and FVIII deficiency 4. Plasminogen deficiency 5. Decreased tissue plasminogen activator 6. Afibrinogenemia/hypofibrinogenemia/dysfibrinogenemia Exclusion Criteria: None Bleeding NOS Cohort Inclusion Criteria: Participants who meet the following inclusion criteria are eligible for enrollment into this cohort: 1. Have a bleeding phenotype as indicated by an age-adjusted abnormal ISTH Bleeding Assessment Tool score with an unknown diagnosis; OR 2. Connective tissue disorder with bleeding tendency as indicated by an age-adjusted abnormal ISTH Bleeding Assessment Tool score Exclusion Criteria: None Thrombosis/Thrombophilia Cohort Inclusion Criteria Participants who meet the following inclusion criteria are eligible for enrollment into this cohort: 1. Have a prior history of arterial or venous thrombosis 2. Patients with a known congenital or acquired thrombophilia with or without a thrombosis a. Common congenital thrombophilias:: i. Protein C deficiency ii. Protein S deficiency iii. Antithrombin deficiency iv. Factor V Leiden v. Prothrombin gene mutation b. Rare genetic factors i. Hyperhomocysteinemia c. Indeterminate genetic factors i. Elevated factor VIII ii. Elevated factor IX iii. Elevated factor XI iv. Elevated lipoprotein (a) d. Acquired thrombophilias i. Lupus anticoagulant ii. Anti-cardiolipin antibodies/Beta2 glycoprotein antibodies iii. Antiphospholipid syndrome Exclusion Criteria 1. Acquired thrombophilia secondary to medications (birth control pills or hormone replacement therapy, overweight or obesity, smoking, cancer, pregnancy, surgery, injury, prolonged inactivity/bedrest, heart failure, inflammatory bowel disease, or kidney disease Non-Neoplastic Hematologic Conditions Cohort Inclusion Criteria Participants who meet the following inclusion criteria are eligible for enrollment into this cohort: 1. Having any congenital or acquired non-neoplastic hematologic disorder not included in any other cohort Exclusion Criteria None Previously Untreated Patients Arm Eligibility Criteria Inclusion Criteria Diagnosis of congenital hemophilia A (FVIII <40%) or hemophilia B (FIX <40% or below lower limit for age) 1. Age <18 years at time of enrollment 2. Parent or authorized guardian or legally authorized representative (LAR) can provide informed consent 3. Care established at one of the participating HTCs Exclusion Criteria 1. CFC exposure, fresh frozen plasma (FFP), cryoprecipitate, and single donor platelets >3 EDs 2. Concomitant diagnosis with another bleeding disorder 3. History of confirmed inhibitor INHIBIT Module Eligibility Criteria: Inclusion Criteria 1. Diagnosis of severe factor VIII deficiency with baseline factor VIII level <1% 2. Initiating or plan to initiate prophylaxis with emicizumab or factor replacement 3. Factor exposure, plasma/FFP, cryo, and single donor platelets =3 EDs 4. =5 years of age Exclusion Criteria 1. Concomitant diagnosis with bleeding disorder other than hemophilia A 2. Immune disorder 3. Factor exposure, plasma/FFP, cryo, and single donor platelets >3 EDs 4. Previous history or presence of factor VIII inhibitor ALTUVIIIO® Module Eligibility Criteria: Inclusion criteria: - People with severe HA with a baseline FVIII activity of less than 1%. (While inclusion for participation in ATHN Transcends lists <5% FVIII activity, this proposed module will limit enrollment to people with FVIII activity levels of <1%) - <18 years of age - No history of FVIII inhibitor - Sex at birth of male, female, or intersex - Participants may be exposed to unfractionated blood components, no more than one dose of FVIII concentrate other than efanesoctocog alfa and up to three doses of efanesoctocog alfa prior to enrollment - Potential participants who have a history of bleeding will be eligible for participation if they meet all other inclusion criteria Exclusion criteria: - Not meeting all the inclusion criteria - Any exposure to blood components or FVIII replacement products except as described in the inclusion criteria - History of positive inhibitor testing - History of hypersensitivity reactions associated with efanesoctocog alfa administration - Any concurrent clinically significant major disease that, in the investigator's opinion, would make the participant unsuitable for enrollment. - The presence of any additional inherited bleeding disorder diagnosis - Enrollment in a concurrent clinical interventional drug study - Intake of an Investigational Medicinal Product within three months prior to inclusion in this study - Inability to comply with study requirements - Other, unspecified reasons that, in the investigator's opinion, make the participant unsuitable for enrollment. Hemophilia Natural History Arm Eligibility Criteria: Inclusion Criteria 1. Congenital hemophilia A or B of any severity with or without inhibitors receiving a current therapy, a non-factor product, or for whom use of a non-factor product is a possibility. Exclusion Criteria 1. Presence of any known bleeding disorder other than congenital hemophilia A or B 2. Presence of concurrent hemophilia and a second hemostatic defect (low Von Willebrand Factor (VWF) without VWD diagnosis is not excluded) 3. Unable or unwilling to comply with the study arm protocol. Rebinyn® Module Eligibility Criteria Inclusion Criteria: Participants who meet the following inclusion criteria at the time of screening are eligible to enroll in the study module. Rebinyn® Cohort 1. Has provided signed written consent for the Rebinyn® Module before any study-related activities. 2. Male participants, at any age with hemophilia B, naïve or minimally exposed (up to 3 EDs) to nonacog beta pegol treatment at time of study enrollment. 3. Decision to initiate treatment with commercially available nonacog beta pegol has been made by the participant(s)/Legally Authorized Representative(s) (LAR(s)) and the treating physician before and independently from the decision to include the participant in this study. Rebinyn® RWE Cohort 1. Has provided signed written consent for ATHN Transcends Study before any study-related activities. 2. Currently treated with nonacog beta pegol 3. Any age Exclusion Criteria: Participants who fall into any of the following exclusion criteria at the time of screening are not eligible for enrollment into the study module: Rebinyn® Cohort 1. Previous participation in this study. Participation is defined as having given informed consent in this study. 2. Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation, including a diagnosis or suspicion of attention deficit hyperactivity disorder (ADHD) or autism spectrum disorder (ASD) per the discretion of the Principal Investigator. 3. Known or suspected hypersensitivity to nonacog beta pegol or related products. 4. Clinical suspicion or presence of FIX inhibitor at time of inclusion. 5. Inability or unwillingness to undergo the neurological assessment/ structured developmental history. Rebinyn® RWE Cohort 1. None Hemophilia Gene Therapy Outcomes Arm Eligibility Criteria: Inclusion Criteria 1. Hemophilia A or B of any severity with or without inhibitors having received or will receive a hemophilia gene transfer product in the next 6 months. 2. Age 18 years and older 3. Able to give informed consent. Exclusion Criteria None HEMGENIX® Module Eligibility Criteria Inclusion Criteria: HEMGENIX Cohort • Age 18 years of age or older • Treatment with commercial HEMGENIX • Have provided signed written informed consent within 3 months before or within 6 months after HEMGENIX treatment, or within 6 months of when the study is initiated at the treating site. Exclusion Criteria, both cohorts: • Have been treated with etranacogene dezaparvovec in a clinical trial. Congenital Platelet Disorders Arm Eligibility Criteria: Inclusion Criteria 1. Platelet adhesion defect 1. Bernard Soulier syndrome (Defective GPIb-IX-V receptor, impaired adhesion to VWF) 2. Velocardio-facial syndrome/DiGeorge syndrome (Defective GPIb-IX-V receptor) 3. Platelet type vWD (Defective GPIb-IX-V, gain of function interaction between VWF-GP1ba) 2. Platelet aggregation defect 1. Glanzmann thrombasthenia (Defective integrin aIIbß3 (GPIIb/IIIa) 2. Platelet aggregation defect, NOS 3. Agonist receptor defects 1. Epinephrine 2. ADP 3. Collagen 4. Thromboxane A2 4. Platelet signaling defects 1. Cyclooxygenase deficiency (PTGS1 mutation) 2. Phospholipase A2 deficiency 3. Thromboxane synthase deficiency (TBXAS1 mutation) 4. G protein activation defect (GNAS mutation) 5. Scott syndrome (defect in phosphatidyl serine translocation) 5. Platelet Granule disorders 1. Dense granule storage pool disorder • Hermansky Pudlak syndrome - Chediak Higashi syndrome - Griscelli syndrome 2. Alpha granule storage pool disorder • Grey platelet syndrome - Arthrogryposis-Renal Dysfunction-Cholestasis (ARC) syndrome - Quebec platelet disorder - Paris-Trousseau syndrome 3. Combined alpha delta granule deficiency 6. Platelet cytoskeletal structure defects 1. Wiskott Aldrich syndrome 2. MYH9 associated disorders (myosin heavy chain) • May Hegglin syndrome • Fechtner syndrome - Sebastian syndrome - Epstein syndrome 3. Other mutations • FLNA mutations (Filamin) • DIAPH1 (Actin and microtubules) • ACTN1 (alpha actinin) • TPM4 (tropomyosin) - TUBB1 (beta tubulin) 7. Other Congenital thrombocytopenias 1. Familial platelet disorders and predisposition to AML (RUNX1) 2. X linked thrombocytopenia with dyserythropoiesis (GATA1) 3. Congenital amegakaryocytic thrombocytopenia (MPL) Exclusion Criteria 1. Diagnosis of von Willebrand disease (Meeting the definition of VWD or low VWF per most recent international guidelines) 2. Diagnosis of Hemophilia A or Hemophilia B (Factor VIII or IX = 40%) FIX Prophylaxis Cohort • Age 18 years of age or older • Treatment with FIX prophylaxis therapy • Has provided signed written consent at any time for ATHN Transcends Study Glanzmann Thrombasthenia (GT) Module Eligibility Criteria: Inclusion Criteria 1. Participant has signed the informed consent/assent form 2. Participant has flow cytometry or aggregometry or genetics confirmed GT 3. Participant is willing to perform study procedures, including daily bleed tracking for 3 months Exclusion Criteria None

Study Design


Related Conditions & MeSH terms

  • Anemia, Sickle Cell
  • Bleeding Disorder
  • Blood Coagulation Disorders
  • Blood Platelet Disorders
  • Connective Tissue Diseases
  • Connective Tissue Disorder
  • Factor IX Deficiency
  • Factor VIII Deficiency
  • Hematologic Diseases
  • Hematologic Disorder
  • Hemophilia
  • Hemophilia A
  • Hemophilia B
  • Hemorrhage
  • Hemorrhagic Disorders
  • Hemostatic Disorders
  • Platelet Disorder
  • Rare Bleeding Disorder
  • Sickle Cell Disease
  • Thalassemia
  • Thrombophilia
  • Thrombosis
  • Von Willebrand Diseases

Locations

Country Name City State
United States Akron Children's Hospital - Showers Center for Cancer & Blood Disorders Akron Ohio
United States Comprehensive Bleeding Disorders Center at Emory University and Children's Healthcare of Atlanta Atlanta Georgia
United States Emory/Children's Health Care of Atlanta Atlanta Georgia
United States University of Colorado Denver Hemophilia and Thrombosis Center Aurora Colorado
United States Johns Hopkins University Hemophilia Treatment Center Baltimore Maryland
United States Massachusetts General Hospital Comprehensive Hemophilia and Thrombosis Treatment Center Boston Massachusetts
United States Montefiore Medical Center Bronx New York
United States Western New York BloodCare Buffalo New York
United States Comprehensive Hemophilia Treatment Center, University of North Carolina at Chapel Hill Chapel Hill North Carolina
United States St. Jude Affiliate Clinic at Novant Health Hemby Children's Hospital Charlotte North Carolina
United States Rush University Medical Center Chicago Illinois
United States Cincinnati Children's Hospital Medical Center, Hemophilia & Thrombosis Center Cincinnati Ohio
United States University of Cincinnati Medical Center Hemophilia Treatment Center Cincinnati Ohio
United States University Hospitals Health System Cleveland Cleveland Ohio
United States Nationwide Children's Hospital Columbus Columbus Ohio
United States North Texas Comprehensive Hemophilia Treatment Center Dallas Texas
United States North Texas Hemophilia and Thrombosis Program - Pediatric Program / Center for Cancer & Blood Disorders Dallas Texas
United States Dayton Children's Hemostasis and Thrombosis Center Dayton Ohio
United States Central Michigan Children's Hospital of Michigan Detroit Michigan
United States Henry Ford Health System Bleeding and Thrombosis Treatment Center Detroit Michigan
United States Fort Worth Bleeding Disorders Program Fort Worth Texas
United States University of Florida Hemophilia Treatment Center Gainesville Florida
United States Hemophilia Outreach Center Green Bay Green Bay Wisconsin
United States East Carolina University Hemophilia Treatment Center Greenville North Carolina
United States Gulf States Hemophilia and Thrombophilia Center Houston Texas
United States Texas Children's Hemophilia & Thrombosis Center/Baylor College of Medicine Houston Texas
United States Northwell Health Hemostasis and Thrombosis Center at Long Island Jewish and Cohen Children's Medical Center Hyde Park New York
United States Indiana Hemophilia and Thrombosis Center Indianapolis Indiana
United States Iowa Hemophilia and Thrombosis Center Iowa City Iowa
United States Children's Mercy Hospital - Kansas City Kansas City Missouri
United States Cure 4 The Kids Foundation Las Vegas Nevada
United States Arkansas Center for Bleeding Disorders Little Rock Arkansas
United States Orthopaedic Institute for Children HTC Los Angeles California
United States Mississippi Center for Advanced Medicine Madison Mississippi
United States St. Jude Children's Research Hospital Memphis Tennessee
United States Comprehensive Center for Bleeding Disorders Milwaukee Wisconsin
United States Vanderbilt University Medical Center Nashville Tennessee
United States Yale Hemophilia Treatment Center New Haven Connecticut
United States Louisiana Center for Bleeding and Clotting Disorders, Tulane University New Orleans Louisiana
United States Weill Cornell Medical College - New York Presbyterian Hospital New York New York
United States Newark Beth Israel Medical Center - Hemophilia Center Newark New Jersey
United States Arnold Palmer Hospital for Children - The Haley Center for Children's Cancer and Blood Disorders Orlando Florida
United States Bleeding and Clotting Disorders Institute Peoria Illinois
United States Children's Hospital of Philadelphia Philadelphia Pennsylvania
United States Penn Comprehensive Hemophilia and Thrombophilia Program/Hospital of the University of Pennsylvania Philadelphia Pennsylvania
United States Arizona Hemophilia and Thrombosis Treatment Center at Phoenix Children's Hospital Phoenix Arizona
United States Hemophilia Center of Western Pennsylvania Pittsburgh Pennsylvania
United States Rhode Island Hospital Hemostasis and Thrombosis Center Providence Rhode Island
United States Hemostasis and Thrombosis Center of Nevada Reno Nevada
United States American Thrombosis and Hemostasis Network Rochester New York
United States Mayo Comprehensive Hemophilia Center Rochester Minnesota
United States University of California at Davis Hemophilia Treatment Center Sacramento California
United States The John Bouhasin Center for Children with Bleeding Disorders Saint Louis Missouri
United States Johns Hopkins All Children's Hospital Saint Petersburg Florida
United States Johns Hopkins All Children's Hospital Saint Petersburg Florida
United States South Texas Comprehensive Hemophilia and Thrombophilia Treatment Center San Antonio Texas
United States Loma Linda Hemoglobinopathy and Inherited Bleeding Disorder Program San Bernardino California
United States Hemophilia & Thrombosis Treatment Center at UC San Diego Health San Diego California
United States Rady Children's Hospital San Diego San Diego California
United States Willett Children's Hemophilia Treatment Center at Memorial Health Savannah Georgia
United States Maine Hemophilia and Thrombosis Center Scarborough Maine
United States Washington Center for Bleeding Disorders Seattle Washington
United States Louisiana Center for Advanced Medicine Slidell Louisiana
United States St. Joseph's Hospital Center for Bleeding & Clotting Disorders Tampa Florida
United States Northwest Ohio Hemophilia Treatment Center at the Toledo Hospital Toledo Ohio
United States Children's National Hemophilia Center Washington District of Columbia
United States Georgetown University Washington District of Columbia
United States Wake Forest University Health Sciences Winston-Salem North Carolina

Sponsors (8)

Lead Sponsor Collaborator
American Thrombosis and Hemostasis Network CSL Behring, Genentech, Inc., Hemab Therapeutics, Hemophilia of Georgia, Inc., Novo Nordisk A/S, Pfizer, Sanofi

Country where clinical trial is conducted

United States, 

References & Publications (8)

Braunholtz DA, Edwards SJ, Lilford RJ. Are randomized clinical trials good for us (in the short term)? Evidence for a "trial effect". J Clin Epidemiol. 2001 Mar;54(3):217-24. doi: 10.1016/s0895-4356(00)00305-x. — View Citation

https://www.clinicaltrials.gov/ct2/results?cond=Hematologic+Diseases&term=&cntry=&state=&city=&dist=. Accessed 04 Jul 2019

https://www.fda.gov/drugs/resources-information-approved-drugs/hematologyoncology-cancer-approvals-safety-notifications. Accessed 04 Jul 2019

Iorio A, Keepanasseril A, Foster G, Navarro-Ruan T, McEneny-King A, Edginton AN, Thabane L; WAPPS-Hemo co-investigator network. Development of a Web-Accessible Population Pharmacokinetic Service-Hemophilia (WAPPS-Hemo): Study Protocol. JMIR Res Protoc. 2016 Dec 15;5(4):e239. doi: 10.2196/resprot.6558. — View Citation

Konkle BA, Recht M; members of Working Group 2, the NHLBI State of the Science Workshop on factor VIII inhibitors: Generating a national blueprint for future research. The national blueprint for 21st century data and specimen collection and observational cohort studies: NHLBI State of the Science Workshop on factor VIII inhibitors. Haemophilia. 2019 Jul;25(4):590-594. doi: 10.1111/hae.13772. — View Citation

Unger JM, Barlow WE, Martin DP, Ramsey SD, Leblanc M, Etzioni R, Hershman DL. Comparison of survival outcomes among cancer patients treated in and out of clinical trials. J Natl Cancer Inst. 2014 Mar;106(3):dju002. doi: 10.1093/jnci/dju002. Epub 2014 Mar 13. — View Citation

Weijer C, Freedman B, Fuks A, Robbins J, Shapiro S, Skrutkowska M. What difference does it make to be treated in a clinical trial? A pilot study. Clin Invest Med. 1996 Jun;19(3):179-83. — View Citation

West J, Wright J, Tuffnell D, Jankowicz D, West R. Do clinical trials improve quality of care? A comparison of clinical processes and outcomes in patients in a clinical trial and similar patients outside a trial where both groups are managed according to a strict protocol. Qual Saf Health Care. 2005 Jun;14(3):175-8. doi: 10.1136/qshc.2004.011478. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other To describe real-world effectiveness of therapies by evaluating for Goal attainment Measured by GOAL-Hem for those participants that opt into this measurement 15 years
Other To describe real-world effectiveness of therapies by evaluating for Patient Reported Outcomes (PROs) Measured by the Patient Reported Outcomes Measurement Information System (PROMIS) Profile 29/25/Parent Proxy 15 years
Other To describe real-world effectiveness of therapies by evaluating treatment adherence Measured by the Global Adherence Rating (GAR) 15 years
Other To describe real-world effectiveness of therapies by evaluating health utility Measured by the EQ-5D-5L 15 years
Primary To determine the safety of therapies used in the treatment of participants with congenital or acquired non-neoplastic blood disorders and connective tissue disorders with bleeding tendency. Safety will be measured by those events in the European Safety Surveillance (EUHASS).
Allergic or other acute events
Treatment-emergent side effects of therapy
Transfusion transmitted infections
Inhibitor development
Thrombosis
Cardiovascular events
Malignancies
Neurological events
Death
In addition to the modified EUHASS endpoints, the following events will be collected as adverse events of special interest (AESI):
The occurrence of thrombotic microangiopathies, injection site reactions and cases of potential drug-induced liver injury
The development of anti-drug antibodies, to be measured and confirmed, if feasible
Severe, unanticipated bleeding
Hospitalizations
Glomerulonephritis
Additional safety events of interest (TBD) may be collected. These may be chosen from drug development profiles based on investigational studies, package inserts, and emerging clinical and scientific observations.
15 years
Primary To describe the safety and tolerability of efanesoctocog alfa in previously untreated patients (PUPs) with hemophilia A without a history of inhibitors. Safety and tolerability will be measured by Annualized Bleed Rate (ABR), number of doses to treat a bleed, doses during perioperative surgery, and clinical patient reported outcomes (PROs) in this population. 7 years
Secondary To establish a platform to support study Arms and Modules for participants with bleeding, clotting, other non-neoplastic blood disorders, and connective tissue disorders with bleeding tendency. For each Arm, a brief set of data elements of interests will be developed and reported for study participants. 15 years
Secondary To describe medication dosing regimens in the above conditions. This objective will be evaluated by:
Determining the number of participants who initiate and/or switch treatment with non-factor products and participants' reasons for initiating and/or switching treatment with non-factor products
Determining the number of participants who do not initiate treatment with non-factor products
Determining the number of participants who switch between different non-factor products and the participants' reasons for switching non-factor products
Determining the number of participants who discontinue treatment with non-factor products and participants' reasons for discontinuing treatment with non-factor products
15 years
Secondary To grow and evolve a biorepository for current and future research through the collection of biospecimens from every person enrolled on this protocol. All participants will have the option of having specimens drawn (about 5mL each) at baseline to be stored in the ATHN Research Biorepository (ARB). 15 years
Secondary To describe real-world effectiveness of therapies by evaluating for Health care utilization Measured by number and type of visits and hospitalizations per year. 15 years
Secondary To describe bleeding events, changes in overall bleeding, and annualized bleeding rate (ABR) as measured by individual bleeding components. This objective will be calculated per ISTH Bleeding Assessment Tool (ISTH BAT), and if applicable, a Pictorial Bleeding Assessment Chart (PBAC), for applicable diagnoses. 15 years
See also
  Status Clinical Trial Phase
Completed NCT02227472 - Working Memory and School Readiness in Preschool-Aged Children With Sickle Cell Disease
Recruiting NCT06301893 - Uganda Sickle Surveillance Study (US-3)
Completed NCT02522104 - Evaluation of the Impact of Renal Function on the Pharmacokinetics of SIKLOS ® (DARH) Phase 4
Recruiting NCT04688411 - An mHealth Strategy to Improve Medication Adherence in Adolescents With Sickle Cell Disease N/A
Terminated NCT03615924 - Effect of Ticagrelor vs. Placebo in the Reduction of Vaso-occlusive Crises in Pediatric Patients With Sickle Cell Disease Phase 3
Not yet recruiting NCT06300723 - Clinical Study of BRL-101 in Severe SCD N/A
Recruiting NCT03937817 - Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
Completed NCT04917783 - Health Literacy - Neurocognitive Screening in Pediatric SCD N/A
Completed NCT04134299 - To Assess Safety, Tolerability and Physiological Effects on Structure and Function of AXA4010 in Subjects With Sickle Cell Disease N/A
Completed NCT02580565 - Prevalence of Problematic Use of Equimolar Mixture of Oxygen and Nitrous Oxide and Analgesics in the Sickle-cell Disease
Recruiting NCT04754711 - Interest of Nutritional Care of Children With Sickle Cell Disease on Bone Mineral Density and Body Composition N/A
Completed NCT04388241 - Preliminary Feasibility and Efficacy of Behavioral Intervention to Reduce Pain-Related Disability in Pediatric SCD N/A
Recruiting NCT05431088 - A Phase 2/3 Study in Adult and Pediatric Participants With SCD Phase 2/Phase 3
Completed NCT01158794 - Genes Influencing Iron Overload State
Recruiting NCT03027258 - Point-of-Delivery Prenatal Test Results Through mHealth to Improve Birth Outcome N/A
Withdrawn NCT02960503 - Macrolide Therapy to Improve Forced Expiratory Volume in 1 Second in Adults With Sickle Cell Disease Phase 1/Phase 2
Completed NCT02620488 - A Brief Laboratory-Based Hypnosis Session for Pain in Sickle Cell Disease N/A
Completed NCT02567682 - Drug Interaction Study of GBT440 With Caffeine, S-warfarin, Omeprazole, and Midazolam in Healthy Subjects Phase 1
Completed NCT02567695 - A Single-Dose Relative Bioavailability Study Of GBT440 300 mg Capsules in Healthy Subjects Phase 1
Withdrawn NCT02630394 - A Pilot Study of Azithromycin Prophylaxis for Acute Chest Syndrome in Sickle Cell Disease Phase 1